Recent reports showing successful inhibition of cancer and leukemia cell growth using histone deacetylase inhibitor (HDACi) compounds have highlighted the potential use of HDACi as anti-cancer agents. However, high incidence of toxicity and low stability in vivo were observed with hydroxamic acid-based HDACi such as suberoylanilide hydroxamic acid (SAHA), thus limiting its clinical applicability. In this study, we found that a novel non-hydroxamate HDACi NCH-51 could inhibit the cell growth of a variety of lymphoid malignant cells through apoptosis induction, more effectively than SAHA. Activation of caspase-3, -8 and -9, but not -7 was detected after the treatment with NCH-51. Gene expression profiles showed that NCH-51 and SAHA similarly upregulated p21 and downregulated anti-apoptotic molecules including survivin, bcl-w and c-FLIP. Proteome analysis using two-dimensional electrophoresis revealed that NCH-51 upregulated anti-oxidant molecules including peroxiredoxin 1 and 2 and glutathione S-transferase at the protein level. Interestingly, NCH-51 induced reactive oxygen species (ROS) after 8 h whereas SAHA continuously declined ROS. Pretreatment with an antioxidant, N-acetyl-L-cysteine, abolished the cytotoxicity of NCH-51. These findings suggest that NCH-51 exhibits cytotoxicity by sustaining ROS at the higher level greater than SAHA. This study indicates the therapeutic efficacy of NCH-51 and novel insights for anti-HDAC therapy.
Introduction
Histone deacetylase (HDAC) is responsible for deacetylation of histone or non-histone substrates. [1] [2] [3] Deacetylation of histone converts local chromatin into repressive configuration, resulting in the transcriptional repression. 2, 3 The aberrant recruitment of HDAC is closely associated with leukemogenesis through silencing of expression of the genes involved in hematopoietic cell differentiation. 4 In addition, subsequent studies demonstrated that the malignant phenotypes of solid tumors could be ascribed to the aberrant activation of HDAC and deacetylation of the histone proteins adjacent to tumor suppressor genes. 5, 6 Thus, a number of small-molecule HDAC inhibitors (HDACi) have been developed as anti-cancer agents. 1, 7 In fact, HDACi compounds were shown to induce cell cycle arrest, differentiation and apoptosis in a variety of malignant cells. 1, 7 Suberoylanilide hydroxamic acid (SAHA) (also known as vorinostat) belongs to a hydroxamic acid-based hybrid polar compound and is a prototypic compound of HDACi. 7 Phase I clinical trials with refractory solid tumors and hematological malignancies by SAHA revealed frequent toxicities including dehydration, fatigue, diarrhea, anorexia and cytopenia, in spite of significant clinical benefits. 8 In addition, a poor pharmacokinetics of SAHA was noted. 8 Other hydroxamic acid-based derivatives showed similar therapeutic profiles.
9,10 Thus, we have attempted to develop a nonhydroxamate HDACi to overcome these problems. A novel HDACi NCH-51 was designed based on SAHA by replacement of the hydroxamic acid by acylated thiol group. NCH-51 could inhibit HDACs as strongly as SAHA and inhibited the cell growth of various solid tumor cell lines in vitro (mean IC 50 values of NCH-51 and SAHA are 3.8 and 3.7 mM, respectively). 11 Unlike SAHA, NCH-51 is stable in human plasma at the remaining rate of approximately 51% after 24 h of administration (unpublished data).
Recent findings suggest that HDACi may have additional effects other than transcriptional interference. Although it is well established that HDACi upregulates gene expression of tumor suppressors such as p21 through histone hyperacetylation, [12] [13] [14] HDACi does not always upregulate gene expression but induces malignant cell death by downregulating gene expression such as anti-apoptotic genes. In addition, some HDACi compounds exhibited anti-cancer effects through acetylation of non-histone substrates such as heat-shock protein 90 (HSP90), 15 a-tubulin, 16 p53 17 and nuclear factor-kB. 18 For example, Bali et al. 15 reported that HDACi caused leukemia cell death by hyperacetylation of HSP90. Hideshima et al. 19 demonstrated that tubacin, a specific HDAC6 inhibitor, was effective in augmenting cell death mediated by bortezomib, a proteasome inhibitor, by inhibiting the protein degradation through blocking aggresome activity. Thus, the cell growth inhibitory action of HDACi could be exhibited at the protein expression level.
Here we demonstrate the therapeutic efficacy of NCH-51 on lymphoid malignant cells. NCH-51 induced cell death, more strongly than SAHA. We analyzed the protein expression profiles and found that NCH-51 modulated the expression of antioxidant molecules at the protein level. NCH-51 sustained the intracellular reactive oxygen species (ROS) greater than SAHA. A human acute T-cell leukemia cell line, Jurkat, ATL cell lines,  MT-2, ATL-102 and ED-40515(À), chronic lymphocytic leukemia cell lines, MEC2 and MO1043, Burkitt's lymphoma cell  lines, Raji and Daudi and multiple myeloma cell lines, U266,  XG7, KM5, ILKM-2 and RPMI-8226 were used in this study as described previously. [20] [21] [22] [23] [24] For normal controls, peripheral blood mononuclear cells (PBMCs) were obtained from four independent healthy donors upon informed consent after the approval of Institutional Ethical Committee. All cells were cultured in RPMI-1640 medium, supplemented with 10% fetal bovine serum at 371C in a 5% CO 2 incubator. NCH-51, a novel nonhydroxamate HDACi, and SAHA, a conventional hydroxamate HDACi, were synthesized by us as described previously.
Materials and methods

Cell lines and reagents
11
NCH-51 and SAHA were dissolved in dimethyl sulfoxide at 50 mM and stored at À201C. An antioxidant compound N-acetyl-L-cysteine (NAC) was purchased from Sigma (St Louis, MS, USA).
Growth inhibition assay
Growth inhibitory effect of HDACi was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (Sigma) as described previously. 25 Briefly, approximately 1-10 Â 10 4 cells per 100 ml were cultured in 96-well plate in triplicates at 371C. Optical densities (OD) at 570 and 630 nm were measured with a multiplate reader. Cell growth (%) was calculated as follows: (OD 630 -OD 570 of the samples/OD 630 -OD 570 of the control) Â 100.
Apoptosis and cell cycle analysis
Apoptosis and cell cycle analyses were performed as described previously. 20 For apoptosis analysis, the cells were treated with or without HDACi for 18 h, and incubated with fluorescein isothiocyanate (FITC)-conjugated annexin V (MBL, Nagoya, Japan). The cell numbers of annexin V-positive cells were analyzed by flowcytometry (FACScan, BD Bioscience, San Jose, CA, USA) and CellQuest analysis program (BD Bioscience). For cell cycle analysis, the cells were incubated with or without HDACi for 24 h, washed with cold phosphate-buffered saline (PBS), and fixed with 70% ethanol. After incubation with RNase A (Qiagen, Alameda, CA, USA), the cell pellets were resuspended in PBS containing propidium iodide (Sigma). DNA content of each cell preparation was analyzed by flowcytometry.
Protein extraction for proteome analysis
Proteome analysis was performed according to Seike et al. 26 U266 cells were incubated with or without 3 mM NCH-51 for 18 h. The cell pellets were washed with cold PBS and then treated with 10%trichloroacetic acid for 30 min on ice. After washing with PBS, the pellets were collected and resuspended in lysis buffer (30 mM Tris-HCl (pH, 8.5), 7 M urea, 2 M thiourea, 3% 3-((3-chlamidopropyl) dimethylammonio)-1-propanesulfonic acid and 1% Triton X-100). Samples were then subjected to a Dounce homogenizer for 30 strokes and sonicated for 5 min in a sonicator (UCW-201, Cosmobio Co. Ltd., Tokyo, Japan). After incubation for 30 min, the samples were centrifuged at 10 000 Â g for 30 min followed by ultracentrifugation at 100 000 Â g for 1 h, and the supernatants were collected. Protein concentration was determined by 2D-Quant kit (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA). Fifty micrograms of each protein extract, adjusted to pH 8.5, were labeled with 200 pmol of minimal dye CyDye (GE Healthcare Bio-Sciences Corp.). NCH-51-treated samples and untreated control proteins were labeled with Cy3 and Cy5, respectively. Internal control, consisting of half part of each paired sample was labeled with Cy2. Labeling reaction was stopped with the addition of 0.2 mM L-lysine (Sigma) for 10 min on ice. Each labeled sample was mixed into one tube and then incubated with an equal amount of lysis buffer for 10 min on ice. The final volume was adjusted to 450 ml with DeStreak Rehydration Solution and 0.5% IPG buffer (GE Healthcare Bio-Sciences Corp.).
Two-dimensional (2D) electrophoresis and image analysis
An immobilized pH gradient gel Immobiline DryStrip (GE Healthcare Bio-Sciences Corp.), with non-linear pH values (3) (4) (5) (6) (7) (8) (9) (10) , was rehydrated with the labeled protein samples at 201C for 12 h. Isoelectric focusing was performed using IPGphor (GE Healthcare Bio-Sciences Corp.) at 201C for total 65 000 khT. Immobiline DryStrips were then equilibrated for 15 min in the buffer (6 M urea, 1.5 M Tris-HCl (pH 8.8), 30% glycerol, 2% sodium dodecyl sulfate) containing 10 mg/ml dithiothreitol and prolonged for 15 min in the same buffer containing 25 mg/ml iodoacetamide. After equilibration, Immobiline DryStrips were transferred onto 11.5% polyacrylamide gels and run in the EttanDalt Six system (GE Healthcare Bio-Sciences Corp.) at 30 W/gel for 5 h at 201C. The gels were scanned with appropriate wavelengths for excitation and emission using Ettan DIGE Primo (GE Healthcare Bio-Sciences Corp.). Relative quantification of spot intensities and statistical evaluation were carried out with ImageMaster 2D Platinum software (GE Healthcare Bio-Sciences Corp.). The experiments were performed in quadruplicates. The protein spots that were statistically significant between untreated control and treated sample were selected.
Protein identification by mass spectrometry
For mass spectrometric analysis, 400 mg of unlabeled-protein extract was independently applied to 2D electrophoresis. The gel was stained with DeepPurple solution (GE Healthcare BioSciences Corp.) according to the manufacturer's recommendation. The gel image was obtained by scanning with Ettan DIGE Primo and matched to those of analytical gels by using the ImageMaster 2D Platinum software. The spots of interest were picked out, and in-gel protein digestion was carried out with trypsin gold (Promega, Madison, WI, USA) as described. 26 Mass spectrometric analyses were performed by using a MALDI-TOF/ TOF type mass spectrometer AB4700 (Applied Biosystems, Framingham, MA, USA). The proteins were identified through the online search using MASCOT database search engine.
Immunoblot analysis
The cell extracts obtained from cell cultures treated with or without HDACi were subjected to cell extract preparation as described above. The samples were applied to electrophoresis on a 10% polyacrylamide gel and transferred onto a nitrocellulose membrane. The membranes were incubated in TBS-T (10 mM Tris-HCl (pH, 8.0), 150 mM NaCl, 0.1% Tween) with 5% non-fat milk containing 1:1000 diluted primary antibodies against either caspase-9, -8, -7, -3, poly-ADP ribose polymerase Growth inhibitory effect of a novel HDAC inhibitor NCH-51 T Sanda et al (PARP) (Cell Signaling Technology, Danvers, MA, USA), peroxiredoxin 1 (Affinity Bioreagents, Golden, CO, USA), elongation factor-2 or a-tubulin (Santa Cruz, Santa Cruz, CA, USA). Membranes were then rinsed in TBS-T and further incubated with HRP-conjugated secondary antibody (GE Healthcare Bio-Sciences Corp.) in TBS-T with 5% non-fat milk. Each protein was detected by SuperSignal (PIERCE, Rockford, IL, USA).
Detection of ROS
ROS content was measured as described previously. 27 After treatment with HDACi, the cells were incubated with an oxidation-sensitive fluorescent probe 2 0 , 7 0 -dichlorofluorescein diacetate (H 2 -DCFDA) (Molecular Probes Inc., Eugene, OR, USA) at a final concentration of 5 mM for 30 min. The cells were washed and resuspended in PBS, and then ROS amount was measured by flowcytometry.
Results
NCH-51 induces apoptosis greater than SAHA
We first evaluated the growth inhibitory effects of NCH-51 on a variety of lymphoid malignant cell lines ( Figure 1a) . A tentative result in a multiple myeloma cell line U266 cells is shown in Figure 1b . In most of the cell lines including U266 cells, NCH-51 exhibited a stronger growth inhibitory effect than SAHA at 3 mM for 24 h treatment, whereas prolonged incubation for 72 h did not show such a difference. It is noted that there was no significance in the growth inhibitory effect on four healthy donor PBMCs between NCH-51 and SAHA (IC 50 values of both agents were higher than 30 mM), suggesting a cell-type specific cytotoxicity of NCH-51. We then analyzed the apoptosis and cell cycle distribution after the treatment with NCH-51 or SAHA. In the six cell lines (Jurkat, ED-40515(À), MEC2, U266, XG7 and ILKM-2), all of which showed a high susceptibility to NCH-51 (IC 50 o3 mM), NCH-51 strongly induced apoptosis greater than SAHA after 24 h treatment as demonstrated by generation of sub-G 1 cells (Figure 1c and Table 1 ). In fact, when U266 cells were treated with NCH-51, cleaved forms of caspase-9, -8, -3 and PARP could be detected after 8 h, evidently at 16 h, although no activation of caspase-7 was detected (Figure 1d ), suggesting that NCH-51 induces apoptosis through both extrinsic (type I) and intrinsic (type II) pathways 28 in the short-term treatment. On the other hand, cell cycle analysis revealed that NCH-51 increased the cell number at G 2 / M-phase and reduced the number at G 1 -or S-phase in most of the cell lines examined (Table 1 , right column). No significant difference in the effects on cell cycle regulation was observed between NCH-51-and SAHA-treated cells. These observations suggest that the apoptosis-inducing activity might be attributable to the difference in the observed growth inhibitory effects between NCH-51 and SAHA.
NCH-51 regulates the expressions of antioxidant molecules at the protein level
To identify the target molecules regulated by NCH-51, we analyzed the RNA and protein expression profiles. cDNA microarray analysis using U266 cells showed that NCH-51 treatment upregulated the expression of p21 and p19 (Supplementary Table 1 ), confirming the previous reports by us 11 and others. [12] [13] [14] On the other hand, NCH-51 downregulated the gene expression of CFLAR (c-FLIP), survivin and BCL2L2 (bcl-w), which act as antiapoptotic molecules. These results suggested that these genes were responsible for the growth inhibitory action of NCH-51, however, there was no notable difference in mRNA expression between NCH-51-and SAHA-treated cells. We then performed the proteome analysis. Whole cell extracts were prepared from U266 cells treated with or without NCH-51, and the protein samples were labeled with fluorescent dyes and applied to 2D electrophoresis (Figure 2a) . By comparing the amounts of cellular proteins, we identified 14 proteins that varied relatively to NCH-51 treatment (Table 2 ). Ten proteins including nucleotide diphosphate kinase A (NDPKA), peroxiredoxin 1 and 2 (PRDX1, 2), glutathione S-transferase P1-1 (GSTP1-1), 14-3-3 zeta/delta, Cl À intracellular channel proteins 1 and 4 (CLIC1, 4), proteasome subunit a3, protease activator 28 b subunit and Rho GDI a were upregulated, and four proteins including alanyl-tRNA synthetase (AARS), elongation factor-2 (EF-2), heat-shock 70 kDa protein 8 (HSPA8) and mitochondrial inner membrane protein, were downregulated after the treatment with NCH-51. Interestingly, some of these proteins upregulated by NCH-51 belong to a class of antioxidant molecules. It is noted that PRDX1 and PRDX2 were upregulated at both mRNA and protein levels, thus they are considered to be upregulated at the gene expression level, whereas most of the proteins were upregulated without induction at the gene expression level. In contrast, EF-2 and HSPA8 were downregulated at the protein level. The effects of NCH-51 and SAHA on the expression of EF-2 and PRDX1 were then verified. As shown in Figure 2b , EF-2 protein level was decreased either by NCH-51 or SAHA in the cell lines such as U266, ED-40515 (À) and XG7 cells that were highly susceptible to HDACi. EF-2 was decreased after 16 h treatment with these HDACi (data not shown). On the other hand, in the cell lines such as MEC2, Daudi and KM5 cells that were less sensitive to HDACi, EF-2 protein level was not significantly changed. PRDX1 protein level was upregulated by the treatment with either NCH-51 or SAHA in ED-40515 (À), U266, XG7 and MEC2 cells. SAHA seemed to upregulate PRDX1 more than NCH-51. Growth inhibitory effect of a novel HDAC inhibitor NCH-51 T Sanda et al
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NCH-51 induces cytotoxic effect through the modulation of intracellular ROS
From the results of proteome analyses, NCH-51 appeared to promote the expression of antioxidant molecules, either at the transcriptional or post-transcriptional level, which prompted us to examine the effect of NCH-51 on the levels of ROS accumulation. Interestingly, the temporal profile of ROS amount in U266 cells treated with NCH-51 appeared to be in a concave shape indicating a gradual suppression of ROS accumulation within the initial 4 h and subsequent induction of ROS (Figure 3a) , whereas the temporal profile with SAHA continuously declined over time. Similar trends were observed with other cell lines (data not shown). As summarized in Table 2 , SAHA was more effective in reducing ROS than NCH-51, and the difference in ROS amount between NCH-51 and SAHA was most evident at 24 h, when the difference in growth inhibitory effect could be observed (Figure 1) . These results suggested a possibility that dynamic state of ROS in each cell could be attributed to the growth inhibitory effect of HDACi. We thus examined whether NAC, a small-molecule antioxidant compound, could modulate the effect of NCH-51 (Figure 3b) . Expectedly, when U266 cells were pretreated with NAC, the NCH-51-mediated cell growth inhibition was abolished. Similar effect was observed in SAHA-treated cells as much as in NCH-51-treated cells (data not shown). These results indicated that high amount of ROS might be necessary for the induction of NCH-51-mediated cytotoxicity.
Discussion
There have been accumulating reports of successful inhibition of cancer cell growth using small-molecule HDACi compounds. 1, 7 Initial studies with SAHA indicated that the mode of action of HDACi might be through upregulating the transcriptionally repressed genes during carcinogenic processes by acetylating the repressive histones. [12] [13] [14] However, recent reports have demonstrated that HDACi compounds also exert anticancer effects through acetylation of non-histone substrates. [15] [16] [17] [18] [19] For example, HDAC6, a microtubule-associated deacetylase, was shown to be responsible for transportation of misfolded proteins to aggresome thus promoting protein degradation.
19,29 Thus, we have attempted to clarify the mechanism of anticancer effects of NCH-51 by examining both mRNA and protein levels.
In this study, we noticed that NCH-51 induced apoptosis in sensitive cell lines greater than SAHA (Figures 1 and 2a and Table 1 ). Analyses of mRNA expression levels in NCH-51-and SAHA-treated cells has revealed that transcriptional repression of antiapoptotic genes, such as survivin, bcl-w and c-FLIP and upregulation of cell cycle regulators, such as p21 and p19, could be attributable to the induction of apoptosis and cell cycle arrest, respectively (Supplementary Table 1 , 2 and Supplementary Figure 1 ), supporting the previous findings by others. [12] [13] [14] There was no difference in the mRNA expression level between NCH-51-and SAHA-treated samples (Supplementary Figure 1) . We have confirmed no difference in inducing activity for acetylation of histone H4 between these two HDACi's (Supplementary Figure 2) . These findings suggest that NCH-51 and SAHA similarly affect gene expression presumably through histone acetylation. We thus examined the effects of these compounds on protein expression profile to understand the difference between NCH-51 and SAHA at the post-transcriptional level.
Interestingly, our proteome analyses revealed the upregulation of some antioxidant molecules including PRDX1, PRDX2 and GSTP1-1 (Table 2 and Figure 2 ). In addition, previous reports indicated that some other proteins identified by the present proteome analysis (Table 2) could be activated by oxidative stress. [30] [31] [32] [33] [34] For example, NDPKA is reported to be activated by ROS and protected the cell from ROS-induced apoptosis. 30, 31 CLIC1 protein contains a redox-active site and is activated during ROS-triggered apoptosis. 32, 33 These findings suggested a possibility that NCH-51 might induce the cytotoxic effect by modulating the intracellular ROS content. In fact, pretreatment with NAC abolished the growth inhibitory effect of NCH-51 (Figure 3b) . These results support the previous findings by others, which showed the ROS accumulation by HDACi. 14, 34, 35 However, in contrast to the previous reports, both NCH-51 and SAHA downregulated the ROS content after 24 h treatment in most of the cell lines tested except for KM5 cells, in which ROS was increased by the treatment with SAHA or NCH-51 (Table 3) . These findings were reproducibly observed. Although we currently do not know the reason why there was a discrepancy between our study and others, we think the timepoint and/or cell characteristics may be different between them. When temporal profiles of ROS accumulation were examined (Figure 3a) , we found a typical bimodal kinetics of the intracellular ROS content after treatment with NCH-51; an initial downregulation and subsequent upregulation of ROS. On the other hand, SAHA did not follow the similar kinetics and the intracellular ROS level gradually and continuously decreased (Figure 3a) . Therefore, it is possible that apparent differences in the ability of cell growth inhibition between NCH-51 and SAHA, may be explained through the different effects on the redox status of cells and induction of antioxidant proteins. Interestingly, our proteome/transcriptome analyses have revealed that the upregulation of antioxidant molecules occurred at either protein or mRNA levels: GSTP1-1 was upregulated by Growth inhibitory effect of a novel HDAC inhibitor NCH-51 T Sanda et al NCH-51 only at the protein level, and PRDX1 and PRDX2 were upregulated primarily at the transcriptional level. These findings suggest that there may be two consequent antioxidative mechanisms by which HDACi modulate ROS accumulation: (i) the mRNA level, acting through induction of transcription of antioxidant molecules de novo, and (ii) the protein level, which was presumably caused by blocking the cellular protein transport/degradation pathway involving aggresome and proteasome. Importantly, we have observed that SAHA but not NCH-51 could induce acetylations of a-tubulin and HSP90 (Supplementary Figure 2 ), suggesting that SAHA might prolong the latter mechanism through blocking the degradation of antioxidant molecules. In fact, SAHA seemed to increase protein expression of PRDX1 greater than NCH-51 (Figure 2b ). Since NCH-51 does not retain antioxidant molecules at the protein level, it induces the accumulation of ROS. Cellular levels of antioxidant molecules have been reported to be associated with the sensitivity to conventional anticancer agents. 36 Therefore, Figure 2 Proteome analysis of the effects of NCH-51. (a). 2D electrophoresis image of whole cell proteins prepared from U266 cells. After U266 cells were treated with or without 3 mM NCH-51 for 18 h, the whole cell extracts were prepared and applied to 2D electrophoresis in quadruplicates. Fourteen spots, whose relative amounts were either increased or decreased by the treatment with NCH-51 in all four gels, were indicated. Each spot number in the image corresponds to those in Table 2 . MW, molecular weight (kDa). pI, isoelectric point. (b) Downregulation of elongation factor-2 (EF-2) and upregulation of peroxiredoxin 1 (PRDX1) by HDACi. The cells were treated with suberoylanilide hydroxamic acid (S) or NCH-51 (N) (3 mM) for 18 h. Whole cell extracts were prepared and subjected to immunoblots with the indicated antibodies. Each value means the ratio of the protein amount to a-tubulin (internal control).
Growth inhibitory effect of a novel HDAC inhibitor NCH-51 T Sanda et al NCH-51 can not only induce apoptosis through ROS accumulation, but also enhance the cytotoxicity of other agents in the combination treatment more efficiently than SAHA.
Our proteome analysis has also identified several proteins other than antioxidant molecules, including EF-2, AARS and HSPA8. We confirmed that EF-2 protein, a member of the GTP- The results are indicated as the ratio of NCH-51-treated sample to untreated control (T/C). Growth inhibitory effect of a novel HDAC inhibitor NCH-51 T Sanda et al binding translational elongation factor family, 37 was specifically decreased in high-sensitivity cell lines such as ED-40515 (À) and U266 cells (Figure 2b ) after 16 h treatment (data not shown). However, gene expression of EF-2 was upregulated after the treatment with NCH-51 ( Table 2 ). This discrepancy indicates a possibility that NCH-51 could induce rapid turnover of EF-2 protein followed by upregulation of RNA expression. Similar effects on EF-2 were also observed with SAHA (Figure 2b ). Since EF-2 has been reported to be inactivated by ROS and lead to inhibition of translation, 38 it is suggested that locally induced ROS by HDACi might induce EF-2 inactivation and degradation presumably by direct oxidation. Although the mechanism by which EF-2 is downregulated by HDACi remains unclear, EF-2 may be used as a feasible surrogate marker to evaluate the susceptibility of HDACi. Similar to EF-2, AARS and HSPA8 were downregulated at the protein level. It is known that HSPA8 are involved in protein folding and transport. 39 Thus, these findings collectively suggest that NCH-51 might arrest protein synthesis and transportation.
In conclusion, our study demonstrates the therapeutic advantage of NCH-51 on growth inhibition of lymphoid malignant cells. Importantly, NCH-51 did not affect the cell growth of normal PBMCs with the effective concentrations on malignant cells (Figure 1b) . In addition to its therapeutic efficacy and selectivity, NCH-51 has additional advantages in clinical use based on its pharmacological features. Therefore, NCH-51 could be a useful anticancer agent against lymphoid malignancies. Growth inhibitory effect of a novel HDAC inhibitor NCH-51 T Sanda et al
